Cargando…
Fatty liver with metabolic disorder, such as metabolic dysfunction‐associated fatty liver disease, indicates high risk for developing diabetes mellitus
INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is diagnosed after excluding other liver diseases. The pathogenesis of NAFLD when complicated by other liver diseases has not been established completely. Metabolic dysfunction‐associated fatty liver disease (MAFLD) involves more metabolic facto...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248428/ https://www.ncbi.nlm.nih.gov/pubmed/35167194 http://dx.doi.org/10.1111/jdi.13772 |
_version_ | 1784739360026918912 |
---|---|
author | Miyake, Teruki Matsuura, Bunzo Furukawa, Shinya Ishihara, Toru Yoshida, Osamu Miyazaki, Masumi Watanebe, Kyoko Shiomi, Akihito Nakaguchi, Hironobu Yamamoto, Yasunori Koizumi, Yohei Tokumoto, Yoshio Hirooka, Masashi Takeshita, Eiji Kumagi, Teru Abe, Masanori Ikeda, Yoshio Iwata, Takeru Hiasa, Yoichi |
author_facet | Miyake, Teruki Matsuura, Bunzo Furukawa, Shinya Ishihara, Toru Yoshida, Osamu Miyazaki, Masumi Watanebe, Kyoko Shiomi, Akihito Nakaguchi, Hironobu Yamamoto, Yasunori Koizumi, Yohei Tokumoto, Yoshio Hirooka, Masashi Takeshita, Eiji Kumagi, Teru Abe, Masanori Ikeda, Yoshio Iwata, Takeru Hiasa, Yoichi |
author_sort | Miyake, Teruki |
collection | PubMed |
description | INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is diagnosed after excluding other liver diseases. The pathogenesis of NAFLD when complicated by other liver diseases has not been established completely. Metabolic dysfunction‐associated fatty liver disease (MAFLD) involves more metabolic factors than NAFLD, regardless of complications with other diseases. This study aimed to clarify the effects of fatty liver occurring with metabolic disorders, such as MAFLD without diabetes mellitus (DM), on the development of DM. MATERIALS AND METHODS: We retrospectively assessed 9,459 participants who underwent two or more annual health check‐ups. The participants were divided into the MAFLD group (fatty liver disease with overweight/obesity or non‐overweight/obesity complicated by metabolic disorders), simple fatty liver group (fatty liver disease other than MAFLD group), metabolic disorder group (metabolic disorder without fatty liver disease), and normal group (all other participants). RESULTS: The DM onset rates in the normal, simple fatty liver, metabolic disorder, and MAFLD groups were 0.51, 1.85, 2.52, and 7.36%, respectively. In the multivariate analysis, the MAFLD group showed a significantly higher risk of DM onset compared with other three groups (P < 0.01). Additionally, the risk of DM onset was significantly increased in fatty liver disease with overweight/obesity or pre‐diabetes (P < 0.01). CONCLUSIONS: Fatty liver with metabolic disorders, such as MAFLD, can be used to identify patients with fatty liver disease who are at high risk of developing DM. Additionally, patients with fatty liver disease complicated with overweight/obesity or prediabetes are at an increased risk of DM onset and should receive more attention. |
format | Online Article Text |
id | pubmed-9248428 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92484282022-07-05 Fatty liver with metabolic disorder, such as metabolic dysfunction‐associated fatty liver disease, indicates high risk for developing diabetes mellitus Miyake, Teruki Matsuura, Bunzo Furukawa, Shinya Ishihara, Toru Yoshida, Osamu Miyazaki, Masumi Watanebe, Kyoko Shiomi, Akihito Nakaguchi, Hironobu Yamamoto, Yasunori Koizumi, Yohei Tokumoto, Yoshio Hirooka, Masashi Takeshita, Eiji Kumagi, Teru Abe, Masanori Ikeda, Yoshio Iwata, Takeru Hiasa, Yoichi J Diabetes Investig Articles INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is diagnosed after excluding other liver diseases. The pathogenesis of NAFLD when complicated by other liver diseases has not been established completely. Metabolic dysfunction‐associated fatty liver disease (MAFLD) involves more metabolic factors than NAFLD, regardless of complications with other diseases. This study aimed to clarify the effects of fatty liver occurring with metabolic disorders, such as MAFLD without diabetes mellitus (DM), on the development of DM. MATERIALS AND METHODS: We retrospectively assessed 9,459 participants who underwent two or more annual health check‐ups. The participants were divided into the MAFLD group (fatty liver disease with overweight/obesity or non‐overweight/obesity complicated by metabolic disorders), simple fatty liver group (fatty liver disease other than MAFLD group), metabolic disorder group (metabolic disorder without fatty liver disease), and normal group (all other participants). RESULTS: The DM onset rates in the normal, simple fatty liver, metabolic disorder, and MAFLD groups were 0.51, 1.85, 2.52, and 7.36%, respectively. In the multivariate analysis, the MAFLD group showed a significantly higher risk of DM onset compared with other three groups (P < 0.01). Additionally, the risk of DM onset was significantly increased in fatty liver disease with overweight/obesity or pre‐diabetes (P < 0.01). CONCLUSIONS: Fatty liver with metabolic disorders, such as MAFLD, can be used to identify patients with fatty liver disease who are at high risk of developing DM. Additionally, patients with fatty liver disease complicated with overweight/obesity or prediabetes are at an increased risk of DM onset and should receive more attention. John Wiley and Sons Inc. 2022-02-28 2022-07 /pmc/articles/PMC9248428/ /pubmed/35167194 http://dx.doi.org/10.1111/jdi.13772 Text en © 2022 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Articles Miyake, Teruki Matsuura, Bunzo Furukawa, Shinya Ishihara, Toru Yoshida, Osamu Miyazaki, Masumi Watanebe, Kyoko Shiomi, Akihito Nakaguchi, Hironobu Yamamoto, Yasunori Koizumi, Yohei Tokumoto, Yoshio Hirooka, Masashi Takeshita, Eiji Kumagi, Teru Abe, Masanori Ikeda, Yoshio Iwata, Takeru Hiasa, Yoichi Fatty liver with metabolic disorder, such as metabolic dysfunction‐associated fatty liver disease, indicates high risk for developing diabetes mellitus |
title | Fatty liver with metabolic disorder, such as metabolic dysfunction‐associated fatty liver disease, indicates high risk for developing diabetes mellitus |
title_full | Fatty liver with metabolic disorder, such as metabolic dysfunction‐associated fatty liver disease, indicates high risk for developing diabetes mellitus |
title_fullStr | Fatty liver with metabolic disorder, such as metabolic dysfunction‐associated fatty liver disease, indicates high risk for developing diabetes mellitus |
title_full_unstemmed | Fatty liver with metabolic disorder, such as metabolic dysfunction‐associated fatty liver disease, indicates high risk for developing diabetes mellitus |
title_short | Fatty liver with metabolic disorder, such as metabolic dysfunction‐associated fatty liver disease, indicates high risk for developing diabetes mellitus |
title_sort | fatty liver with metabolic disorder, such as metabolic dysfunction‐associated fatty liver disease, indicates high risk for developing diabetes mellitus |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248428/ https://www.ncbi.nlm.nih.gov/pubmed/35167194 http://dx.doi.org/10.1111/jdi.13772 |
work_keys_str_mv | AT miyaketeruki fattyliverwithmetabolicdisordersuchasmetabolicdysfunctionassociatedfattyliverdiseaseindicateshighriskfordevelopingdiabetesmellitus AT matsuurabunzo fattyliverwithmetabolicdisordersuchasmetabolicdysfunctionassociatedfattyliverdiseaseindicateshighriskfordevelopingdiabetesmellitus AT furukawashinya fattyliverwithmetabolicdisordersuchasmetabolicdysfunctionassociatedfattyliverdiseaseindicateshighriskfordevelopingdiabetesmellitus AT ishiharatoru fattyliverwithmetabolicdisordersuchasmetabolicdysfunctionassociatedfattyliverdiseaseindicateshighriskfordevelopingdiabetesmellitus AT yoshidaosamu fattyliverwithmetabolicdisordersuchasmetabolicdysfunctionassociatedfattyliverdiseaseindicateshighriskfordevelopingdiabetesmellitus AT miyazakimasumi fattyliverwithmetabolicdisordersuchasmetabolicdysfunctionassociatedfattyliverdiseaseindicateshighriskfordevelopingdiabetesmellitus AT watanebekyoko fattyliverwithmetabolicdisordersuchasmetabolicdysfunctionassociatedfattyliverdiseaseindicateshighriskfordevelopingdiabetesmellitus AT shiomiakihito fattyliverwithmetabolicdisordersuchasmetabolicdysfunctionassociatedfattyliverdiseaseindicateshighriskfordevelopingdiabetesmellitus AT nakaguchihironobu fattyliverwithmetabolicdisordersuchasmetabolicdysfunctionassociatedfattyliverdiseaseindicateshighriskfordevelopingdiabetesmellitus AT yamamotoyasunori fattyliverwithmetabolicdisordersuchasmetabolicdysfunctionassociatedfattyliverdiseaseindicateshighriskfordevelopingdiabetesmellitus AT koizumiyohei fattyliverwithmetabolicdisordersuchasmetabolicdysfunctionassociatedfattyliverdiseaseindicateshighriskfordevelopingdiabetesmellitus AT tokumotoyoshio fattyliverwithmetabolicdisordersuchasmetabolicdysfunctionassociatedfattyliverdiseaseindicateshighriskfordevelopingdiabetesmellitus AT hirookamasashi fattyliverwithmetabolicdisordersuchasmetabolicdysfunctionassociatedfattyliverdiseaseindicateshighriskfordevelopingdiabetesmellitus AT takeshitaeiji fattyliverwithmetabolicdisordersuchasmetabolicdysfunctionassociatedfattyliverdiseaseindicateshighriskfordevelopingdiabetesmellitus AT kumagiteru fattyliverwithmetabolicdisordersuchasmetabolicdysfunctionassociatedfattyliverdiseaseindicateshighriskfordevelopingdiabetesmellitus AT abemasanori fattyliverwithmetabolicdisordersuchasmetabolicdysfunctionassociatedfattyliverdiseaseindicateshighriskfordevelopingdiabetesmellitus AT ikedayoshio fattyliverwithmetabolicdisordersuchasmetabolicdysfunctionassociatedfattyliverdiseaseindicateshighriskfordevelopingdiabetesmellitus AT iwatatakeru fattyliverwithmetabolicdisordersuchasmetabolicdysfunctionassociatedfattyliverdiseaseindicateshighriskfordevelopingdiabetesmellitus AT hiasayoichi fattyliverwithmetabolicdisordersuchasmetabolicdysfunctionassociatedfattyliverdiseaseindicateshighriskfordevelopingdiabetesmellitus |